Literature DB >> 6404846

Adriamycin induced immunomodulation: dependence upon time of administration.

M J Ehrke, V Tomazic, K Ryoyama, S A Cohen, E Mihich.   

Abstract

The immunomodulating capabilities of the anti-neoplastic agent, Adriamycin, were investigated. The day of Adriamycin administration to mice was varied from -15 to -1, day 0 being when mice were either immunized or sacrificed and their spleen cells sensitized in culture. Humoral and cellular immune responses against allogeneic or xenogeneic cellular antigens in mice and in culture, as well as phagocytic and ADCC activities were evaluated using spleen cell populations. The cellular responses and phagocytic activities were affected in a cyclical manner with time after Adriamycin's administration. Peaks of increased activity were seen subsequent to day -5 and day -11, administration and low activities following day -1, -3 and day -7, -9 administration. The humoral responses were not affected in a biphasic manner but single peaks of increased activity were seen which corresponded to the times of low cellular cytolytic and phagocytic activities. The ADCC was independent of time of Adriamycin administration. The significance of these findings to the design of therapeutic protocols is discussed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6404846     DOI: 10.1016/0192-0561(83)90070-x

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  7 in total

1.  Chemotherapy: A new standard combination for recurrent ovarian cancer?

Authors:  Robert C Bast; Maurie Markman
Journal:  Nat Rev Clin Oncol       Date:  2010-10       Impact factor: 66.675

2.  Indomethacin modulation of adriamycin-induced effects on multiple cytolytic effector functions.

Authors:  D L Maccubbin; S A Cohen; M J Ehrke
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

3.  Augmentation of the generation of lymphokine-activated killer cells after a single dose of mitomycin C in cancer patients.

Authors:  S Nanbara; S Arinaga; T Akiyoshi
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

4.  Augmentation of the generation of cell-mediated cytotoxicity in culture by mitomycin C.

Authors:  T Akiyoshi; S Arinaga; H Tsuji
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

5.  Adriamycin induced resistance of sensitive K 562 cells to natural killer lymphocyte attack.

Authors:  H Benoist; C Madoulet; J C Jardillier; A Desplaces
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

6.  Systemic activation of macrophages by liposome-entrapped muramyl tripeptide in mice pretreated with the chemotherapeutic agent adriamycin.

Authors:  G Hisano; I J Fidler
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

7.  A trial of postoperative adjuvant combination chemo-immunotherapy for stage IV gastric carcinoma.

Authors:  T Akiyoshi; S Arinaga; K Takamuku; T Wada; F Koba; H Tsuji
Journal:  Jpn J Surg       Date:  1988-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.